Literature DB >> 23937260

Cellular immune dysfunction in immune thrombocytopenia (ITP).

Christopher G J McKenzie1, Li Guo, John Freedman, John W Semple.   

Abstract

Over the past decades, a wealth of information has been reported about the pathogenic features of immune thrombocytopenia (ITP). To this day, however, it is unclear whether the immune abnormalities associated with ITP play causative roles in the disease or are secondary epiphenomena brought on by the inflammatory processes that are associated with the disorder. Like the majority of all autoimmune diseases, ITP is an organ-specific disease and abnormalities in immune cell types, such as antigen-presenting cells (APC), T cells and B cells have been shown to play some sort of role in the initiation and/or perpetuation of the disease. This review will discuss recent advances in understanding three immune cells important in ITP pathophysiology: APC, T cells and B cells, and will review how they interact with each other to initiate and perpetuate ITP, particularly the chronic form of the disorder. It will also focus on new data related to the genetics of the disorder and discuss relevant animal models of ITP.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  B cells; Immune thrombocytopenia (ITP); T cells; antigen presenting cells; autoimmunity

Mesh:

Year:  2013        PMID: 23937260     DOI: 10.1111/bjh.12480

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  36 in total

1.  Imbalanced expression of Bcl-xL and Bax in platelets treated with plasma from immune thrombocytopenia.

Authors:  Jianlin Qiao; Yun Liu; Depeng Li; Yulu Wu; Xiaoqian Li; Yao Yao; Mingshan Niu; Chunling Fu; Hongchun Li; Ping Ma; Zhenyu Li; Kailin Xu; Lingyu Zeng
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

Review 2.  Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?

Authors:  J E Vaughn; F Anwer; H J Deeg
Journal:  Vox Sang       Date:  2015-07-14       Impact factor: 2.144

3.  CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

Authors:  Li Ma; Elisa Simpson; June Li; Min Xuan; Miao Xu; Laura Baker; Yan Shi; Issaka Yougbaré; Xiaozhong Wang; Guangheng Zhu; Pingguo Chen; Gerald J Prud'homme; Alan H Lazarus; John Freedman; Heyu Ni
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

Review 4.  The significance and management of thrombocytopenia in antiphospholipid syndrome.

Authors:  Bahar Artim-Esen; Reyhan Diz-Küçükkaya; Murat İnanç
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

5.  Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.

Authors:  Joseph H Oved; Christina S Y Lee; James B Bussel
Journal:  J Pediatr       Date:  2017-12       Impact factor: 4.406

6.  Platelets as immune-sensing cells.

Authors:  Rick Kapur; John W Semple
Journal:  Blood Adv       Date:  2016-11-22

7.  Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets.

Authors:  Anne Zufferey; Edwin R Speck; Kellie R Machlus; Rukhsana Aslam; Li Guo; Mark J McVey; Michael Kim; Rick Kapur; Eric Boilard; Joseph E Italiano; John W Semple
Journal:  Blood Adv       Date:  2017-09-08

Review 8.  Megakaryocytes as immune cells.

Authors:  Pierre Cunin; Peter A Nigrovic
Journal:  J Leukoc Biol       Date:  2019-01-15       Impact factor: 4.962

9.  Autoimmune cytopenias and thrombotic thrombocytopenic purpura.

Authors:  Charlotte K Brierley; Sue Pavord
Journal:  Clin Med (Lond)       Date:  2018-08       Impact factor: 2.659

10.  B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy.

Authors:  Paola Giordano; Simona Cascioli; Giuseppe Lassandro; Valentina Marcellini; Fabio Cardinale; Federica Valente; Franco Locatelli; Rita Carsetti
Journal:  Pediatr Res       Date:  2015-10-22       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.